Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer

Park, Ji Hyun; Ryu, Min‐Hee; Kim, Hwa Jung; Ryoo, Baek‐Yeol; Yoo, Changhoon; Park, Inkeun; Park, Young Soo; Oh, Seok‐Young; Yook, Jeong Hwan; Kim, Byung Sik; Kang, Yoon‐Koo

doi:10.1007/s10120-015-0464-5

Cited by 31 publications

(47 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several trials have addressed the effect of the recovery period following curative surgery and start of adjuvant therapy as potential contributors to outcome in other cancers including breast , colorectal , and gastric . In breast cancer, there were conflicting reports, with no difference in disease‐free survival or OS in patients who received adjuvant chemotherapy within the arbitrary cut‐off of 21 days after surgery .…”

Section: Discussionmentioning

confidence: 99%

“…In the context of this study's findings, while "timely" AT should remain the clinical goal after safe recovery for those who undergo upfront pancreatectomy, one should not forego intended AT simply because the initiation date is beyond the theoretical 8-week "window." Several trials have addressed the effect of the recovery period following curative surgery and start of adjuvant therapy as potential contributors to outcome in other cancers including breast [15], colorectal [16], and gastric [17,18]. In breast cancer, there were Journal of Surgical Oncology conflicting reports, with no difference in disease-free survival or OS in patients who received adjuvant chemotherapy within the arbitrary cutoff of 21 days after surgery [19].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Nonetheless, patients with curative gastrectomy continue to experience recurrence during follow-up. More recent studies have shown that the overall 5-year survival rate of gastric cancer has improved because of curative gastrectomy with chemotherapy (2,3). However, death from gastric cancer is almost entirely caused by recurrent diseases (4).…”

Section: Introductionmentioning

confidence: 99%

Characteristics of gastric cancer recurrence five or more years after curative gastrectomy

Shin

Lee

Hong

et al. 2016

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

ObjectiveTo investigate the characteristics of recurrences that occurred 5 or more years after curative resection for gastric cancer.MethodsWe analyzed recurrences among 1,299 patients with gastric cancer who underwent curative operations at the Department of Surgery, Inje University Seoul Paik Hospital between September 1998 and December 2002. Recurrences were classified as within 2 years (early), 2–5 years (intermediate), and more than 5 years (late) after gastrectomy. The clinicopathologic findings of the patients with late recurrence were compared with those of patients in the other two recurrence groups, with special reference to the patterns of recurrence. Both univariate and multivariate analyses were performed, incorporating factors such as operation type, T-stage, N-stage, stage, lymphatic invasion, neural invasion, histology, tumor size, and recurrence site.ResultsAt the time of last follow-up, recurrence occurred in 266 (20.5%) patients. Recurrence times were classified as <2 years (182 patients), 2–5 years (61 patients), or >5 years (23 patients). The late recurrence rate was 8.6%. The occurrence of recurrence >5 years after gastrectomy was significantly correlated with age, operation type, T-stage, N-stage, stage, lymphatic invasion, neural invasion, histology, tumor size, location and recurrence site (P<0.05). The main recurrence patterns in the 23 patients with late recurrence were locoregional metastasis (10 patients, 43.5%), peritoneal seeding (8 patients, 34.8%), hematogenous metastasis (2 patients, 8.7%), and multiple metastasis (3 patients, 13.0%). A multivariate analysis showed that larger tumor size and younger age were independent prognostic factors for late recurrence. Additionally, locoregional and peritoneal recurrences were significantly more common than hematogenous recurrences.ConclusionsAlthough late recurrence was uncommon, younger age and larger tumor size were associated with high risk. Follow-up surveillance is recommended for locoregional and peritoneal metastasis.

show abstract

“…Previous study reported that submucosal layer invasion, lymph node metastasis, and pathological differentiation (tub1 and tub2) were the risk factors for tumor recurrence after surgery for early stage GC 43. On the other hand, another previous study revealed that high age, male, lymphovascular invasion, stage IB (proper muscle invasion or lymph node metastasis), perineural invasion, and elevated tumor marker were independent poor prognostic factors for RFS 44. Although we did not investigate the relationship between GAR and these clinical characteristics of stage I GC which was associated with tumor recurrence, our result indicated that preoperative high GAR (>0.80) was useful for predicting poor prognosis of RFS in stage I GC patients in comparison with low GAR (<0.80).…”

Section: Discussionmentioning

confidence: 96%

“…The recurrence rate in patients with early stage GC was reported to be 1.4%‐3.0% 43, 44. Previous study reported that submucosal layer invasion, lymph node metastasis, and pathological differentiation (tub1 and tub2) were the risk factors for tumor recurrence after surgery for early stage GC 43.…”

Section: Discussionmentioning

confidence: 99%

Preoperative globulin‐to‐albumin ratio predicts outcome after curative resection in patients with gastric cancer

Shioiri

Ishizuka

Shibuya

et al. 2018

Annals of Gastroent Surgery

View full text Add to dashboard Cite

AimThe globulin‐to‐albumin ratio (GAR) is useful for prognostication of patients with various cancers. However, the significance of GAR in gastric cancer (GC) remains unclear. Our purpose was to investigate the relationship between the GAR and outcome after curative resection in GC patients.MethodsThree‐hundred and seventy‐six patients who had undergone curative resection for GC were retrospectively reviewed. Univariate and multivariate analyses using the Cox proportional hazard model were performed to detect clinical characteristics that correlated with overall survival (OS), and their cut‐off values were identified using receiver operating characteristic (ROC) curve analyses. Kaplan–Meier analysis and log‐rank test were used for comparison of OS and relapse‐free survival (RFS).ResultsMultivariate analysis using 17 clinical characteristics selected by univariate analyses revealed that GAR (>0.80/≤0.80) was significantly associated with OS (hazard ratio [HR], 2.305; 95% CI, 1.122‐4.735; P = 0.023), as well as lymph node metastasis (presence/absence) (HR, 2.417; 95% CI, 1.077‐5.426; P = 0.032), neutrophil‐to‐lymphocyte ratio (>2.7/≤2.7) (HR, 2.368; 95% CI, 1.138‐4.930; P = 0.002), and serosal invasion (presence/absence) (HR, 3.443; 95% CI, 1.048‐11.31; P = 0.042). Kaplan–Meier analysis and log‐rank test demonstrated that the OS and RFS of patients with a high GAR (>0.80) were significantly poorer than those with low GAR (≤0.80).ConclusionsThe GAR is a useful predictor of postoperative outcome among GC patients undergoing curative resection.

show abstract

Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer

Cited by 31 publications

References 29 publications

Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis

Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis

Characteristics of gastric cancer recurrence five or more years after curative gastrectomy

Preoperative globulin‐to‐albumin ratio predicts outcome after curative resection in patients with gastric cancer

Contact Info

Product

Resources

About